Urol. praxi. 2016;17(3):117-120 | DOI: 10.36290/uro.2016.030

Papillary renal cell carcinoma - occurrence and parameter

MUDr. Petr Prošvic
Urologické oddělení, Oblastní nemocnice Náchod, a. s.

Malignant tumours of kidney form about 2 percent of the all malignancies. Papillary renal cell carcinoma (PRCC) is discrete group of renal cancers according to WHO 2004 classification. The papillary renal cell carcinomas are divided into two subtypes, type 1 and type 2. Both types differ from each other in histology, genetics, their behaviour and prognosis. There are hereditary forms of the papillary renal cell carcinomas except for sporadic forms of the PRCCs. Study of the hereditary forms contributes to discovery of new targeted therapy. Current targeted therapy is significantly less effective in patients with papillary renal cell carcinoma in comparison to patients with clear cell histology.

Keywords: papillary renal-cell carcinoma, incidence, diagnosis, histopathology, prognosis

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prošvic P. Papillary renal cell carcinoma - occurrence and parameter. Urol. praxi. 2016;17(3):117-120. doi: 10.36290/uro.2016.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS. Novotvary 2011. Praha ÚZIS 2015: 29-31 s.
    2. Lopez-Beltrana A, Scarpellib M, Montironib R, Kirkalic Z. 2004 WHO Classification of the Renal Tumors of the Adults. Eur Urol 2006; 49(5): 798-805. Go to original source... Go to PubMed...
    3. Blath RA, Mancilla-Jimenez R, Stanley RJ. Clinical comparison between vascular and avascular renal cell carcinoma. J Urol 1976; 115(5): 514-519. Go to original source... Go to PubMed...
    4. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10(6): 537-544. Go to PubMed...
    5. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 2012; 22(11): 2089-2100. Go to original source...
    6. Hora M, Hes O a kol. Papilární renální karcinom. Česká urologie 2002; 1: 26-31.
    7. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 1976; 38(6): 2469-2480. Go to original source...
    8. Valenca LB, Hirsch MS, Choueiri TK, Harshman LC. Non-clear cell renal cell carcinoma, part 1: histology. Clin Adv Hematol Oncol 2015; 13(5): 308-313.
    9. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Mamun AA, et al. (Cancer Genome Atlas Research Network). Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2016; 374(2): 135-145. Go to original source...
    10. Prošvic P, Straka V. Výskyt a charakteristika papilárních renálních karcinomů. Brno 2015, Č. 144. Dostupný na WWW: http://www.registracni-system.cz/akce-brnenske-onkologicke-dny-2014/sjezd.php?p=read_abstrakt_program&idabstrakta=115
    11. Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff JW, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk MA, Junker K, Schrader AJ. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer 2012; 48(15): 2347-2352. Go to original source... Go to PubMed...
    12. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R. Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol 2009; 135(6): 799-805. Go to original source... Go to PubMed...
    13. Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK. Racial difference in histologic subtype of renal cell carcinoma. Cancer Med 2013; 2(5): 744-749. Go to original source...
    14. Renshaw AA, Granter SR, Fletcher JA, Kozakewich HP, Corless CL, Perez-Atayde AR. Renal cell carcinomas in children and young adults: increased incidence of papillary architecture and unique subtypes. Am J Surg Pathol 1999; 23(7): 795-802. Go to original source...
    15. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, Moch H. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004; 28(9): 1117-1132. Go to original source... Go to PubMed...
    16. Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, Debré B, Amsellem-Ouazana D. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69(2): 230-235. Go to original source... Go to PubMed...
    17. Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, Dangle P, Shalhav AL, Crist H, Raman JD, Joel DeCastro G, Harik L, Paroder M, Uzzo RG, Kutikov A, Eggener SE. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol 2015. [Epub ahead of print]. DOI 10.1007/s00345-015-1692-3. Go to original source...
    18. Cornejo KM, Dong F, Zhou AG, Wu CL, Young RH, Braaten K, Sadow PM, Nielsen GP, Oliva E. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome. Hum Pathol 2015; 46(10): 1411-1417. Go to original source...
    19. Patel NH, Attwood KM, Hanzly M, Creighton TT, Mehedint DC, Schwaab T, Kauffman EC. Comparative Analysis of Smoking as a Risk Factor among Renal Cell Carcinoma Histological Subtypes. J Urol 2015; 194(3): 640-646. Go to original source... Go to PubMed...
    20. Rubio Marco I, García de Eulate I, Sánchez Rodríguez C, Tirapu Tapiz M, Ovelar Ferrero A, Monreal R. Papillary renal cell carcinoma: When should we suspect it? 2015. Dostupný z: http://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&doi=10.1594/ecr2015/C-1641
    21. Hes O, Hora M. Patologie cystických nádorů ledvin dospělých. Diferenciální diagnóza, prognóza a význam pro klinickou praxi. Urol. Praxi 2010; 11(1): 22-24.
    22. Ferda J, Kastner J, Ferdová E, Mírka H, Baxa J, Hora M, Hes O, Fínek J, Kreuzberg B. Zobrazení solidních nádorů ledvin. Ces Radiol 2012; 66(3): 271-281.
    23. Inci E, Hocaoglu E, Aydin S, Cimilli T. Diffusion-weighted magnetic resonance imaging in evaluation of primary solid and cystic renal masses using the Bosniak classification. Eur J Radiol 2012; 81(5): 815-820. Go to original source... Go to PubMed...
    24. Ferda J, Hora M, Hes O, Reischig T, Kreuzberg B, Mírka H, Ferdová E, Ohlídalová K, Baxa J, Urge T. Computed tomography of renal cell carcinoma in patients with terminal renal impairment. Eur J Radiol 2007; 63(2): 295-301. Go to original source...
    25. Podhola M. Karcinom ledvin dospělých. Onkologie 2009; 3(2): 80-82.
    26. Hes O. International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 2012. Cesk Patol 2014; 50(4): 137-141. Go to PubMed...
    27. Algaba F. Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets. In: Bukowski R, Figlin RA., Motzer R: Renal Cell Carcinoma, Molecular Targets and Clinical Applications. Springer Science + Business Media, New York 2015: s. 15-38. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.